Results 191 to 200 of about 67,431 (260)

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib. [PDF]

Sci Adv
Podszywałow-Bartnicka P, Shine M, Lin J, Neugebauer KM.   +3 more
europepmc   +1 more source

Identification of MBT3T as a new effective therapeutic option in imatinib-resistant gastrointestinal stromal tumors (GISTs). [PDF]

J Exp Clin Cancer Res
Ravegnini G, Esposito D, Gorini F, Marforio TD, Coschina E, Benuzzi E, Simone A, Samaha A, Di Vito A, Rossi M, Hrelia P, Locatelli A, Calvaresi M, Facchinello N, Morigi R, Angelini S.   +15 more
europepmc   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Toward a chemotherapy and allo-HSCT free future: the evolution of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. [PDF]

Front Immunol
Yang Q.
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

A Ponatinib-Associated Transcriptomic Signature: Implications for Cardiovascular Toxicity. [PDF]

Int J Mol Sci
Kong J, Jang J, Kong JH, Lee T.
europepmc   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia. [PDF]

Int J Mol Sci
Basabrain AA, Austin GM, Holcroft AK, Apperley JF, Clark RE, Varadarajan S, Lucas CM.   +6 more
europepmc   +1 more source

A case report of BCR-ABL(+) acute myeloid leukemia and literature review. [PDF]

Front Oncol
Li J, Zheng W, Dong X, Wang J, Liu K.
europepmc   +1 more source

Mechanisms, Clinical Phenotype and Potential Risk Prediction for Cardiovascular Toxicity Induced by Tyrosine Kinase Inhibitors In Chronic Myeloid Leukemia. [PDF]

Dose Response
Zheng H, Huang C, Zhang Z, Su M, Jiang P, Wu G.   +5 more
europepmc   +1 more source